摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5'-amino-2',5'-dideoxy-2'-fuorouridine

中文名称
——
中文别名
——
英文名称
5'-amino-2',5'-dideoxy-2'-fuorouridine
英文别名
5'-amino-2'-fluoro-2',5'-dideoxyuridine;1-((2R,3R,4R,5R)-5-(Aminomethyl)-3-fluoro-4-hydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione;1-[(2R,3R,4R,5R)-5-(aminomethyl)-3-fluoro-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione
5'-amino-2',5'-dideoxy-2'-fuorouridine化学式
CAS
——
化学式
C9H12FN3O4
mdl
——
分子量
245.21
InChiKey
UVSHJHMDPRLJOT-XVFCMESISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    105
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5'-amino-2',5'-dideoxy-2'-fuorouridine4-甲氧基三苯基氯甲烷4-二甲氨基吡啶 吡啶 作用下, 反应 210.0h, 以59%的产率得到5'-amino-2',5'-dideoxy-2'-fuoro-5'-N-(4'-monomethoxytrityl)uridine
    参考文献:
    名称:
    Novel Dideoxynucleoside Derivatives
    摘要:
    本发明公开了由下式[1]所表示的5'-氨基-2'-氟-2',5'-二脱氧核苷衍生物(其中R1表示可能具有保护基团的核酸碱基;R2表示氢原子或氨基的保护基团;R3表示氢原子或羟基的保护基团);通过将该二脱氧核苷衍生物与不溶性载体结合而制备的二脱氧核苷载体结合物质;以及引入了该二脱氧核苷衍生物的寡核苷酸类似物。本发明引入了含有该二脱氧核苷衍生物的寡核苷酸类似物具有优异的热稳定性,当形成双链时也具有高结合亲和力。此外,预计它具有高核酸酶抵抗力。此外,本发明的二脱氧核苷衍生物可用作用于核酸合成的酰胺酯试剂,也可作为将酰胺酯试剂结合到固相上进行核酸固相合成的起始物料。
    公开号:
    US20080064868A1
  • 作为产物:
    描述:
    1-[(2R,3R,4R,5R)-5-(azidomethyl)-3-fluoro-4-hydroxy-tetrahydrofuran-2-yl]pyrimidine-2,4-dione 在 palladium on activated charcoal 氢气 作用下, 以 甲醇 为溶剂, 反应 15.0h, 以85%的产率得到5'-amino-2',5'-dideoxy-2'-fuorouridine
    参考文献:
    名称:
    Novel Dideoxynucleoside Derivatives
    摘要:
    本发明公开了由下式[1]所表示的5'-氨基-2'-氟-2',5'-二脱氧核苷衍生物(其中R1表示可能具有保护基团的核酸碱基;R2表示氢原子或氨基的保护基团;R3表示氢原子或羟基的保护基团);通过将该二脱氧核苷衍生物与不溶性载体结合而制备的二脱氧核苷载体结合物质;以及引入了该二脱氧核苷衍生物的寡核苷酸类似物。本发明引入了含有该二脱氧核苷衍生物的寡核苷酸类似物具有优异的热稳定性,当形成双链时也具有高结合亲和力。此外,预计它具有高核酸酶抵抗力。此外,本发明的二脱氧核苷衍生物可用作用于核酸合成的酰胺酯试剂,也可作为将酰胺酯试剂结合到固相上进行核酸固相合成的起始物料。
    公开号:
    US20080064868A1
点击查看最新优质反应信息

文献信息

  • Novel Dideoxynucleoside Derivatives
    申请人:Kitade Yukio
    公开号:US20080064868A1
    公开(公告)日:2008-03-13
    The present invention discloses a 5′-amino-2′-fluoro-2′,5′-dideoxynucleoside derivative represented by the following formula [1]: (wherein R 1 represents a nucleic acid base which may have a protecting group; R 2 represents a hydrogen atom or a protecting group of an amino group; R 3 represents a hydrogen atom or a protecting group of a hydroxyl group); a dideoxynucleoside-insoluble carrier bound substance prepared by binding said dideoxynucleoside derivative to an insoluble carrier, and an oligonucleotide analogue into which said dideoxynucleoside derivative is introduced. The oligonucleotide analogue being introduced with a dideoxynucleoside derivative of the present invention has excellent thermal stability and also high binding affinity when duplex is formed. Also, it is anticipated that it has high resistance to nucleases. Further, the dideoxynucleoside derivative of the present invention can be used as an amidite reagent to be used for nucleic acid synthesis, and also as a starting material for solid phase synthesis of nucleic acid by binding the amidite reagent to a solid phase.
    本发明公开了由下式[1]所表示的5'-氨基-2'-氟-2',5'-二脱氧核苷衍生物(其中R1表示可能具有保护基团的核酸碱基;R2表示氢原子或氨基的保护基团;R3表示氢原子或羟基的保护基团);通过将该二脱氧核苷衍生物与不溶性载体结合而制备的二脱氧核苷载体结合物质;以及引入了该二脱氧核苷衍生物的寡核苷酸类似物。本发明引入了含有该二脱氧核苷衍生物的寡核苷酸类似物具有优异的热稳定性,当形成双链时也具有高结合亲和力。此外,预计它具有高核酸酶抵抗力。此外,本发明的二脱氧核苷衍生物可用作用于核酸合成的酰胺酯试剂,也可作为将酰胺酯试剂结合到固相上进行核酸固相合成的起始物料。
  • US7629447B2
    申请人:——
    公开号:US7629447B2
    公开(公告)日:2009-12-08
  • Synthesis and properties of siRNAs containing 5′-amino-2′,5′-dideoxy-2′α-fluororibonucleosides
    作者:Yoshihito Ueno、Miki Hirai、Kayo Yoshikawa、Yoshiaki Kitamura、Yoko Hirata、Kazutoshi Kiuchi、Yukio Kitade
    DOI:10.1016/j.tet.2008.08.117
    日期:2008.12
    Short interfering RNAs (siRNAs) containing P3'-> N5' phosphoramidate linkages were successfully synthesized by introducing 2'-deoxy-2'-fluororibonucleoside and 5'-amino-2',5'-dideoxy-2'alpha-fluororibonucleoside in succession. It was found that the introduction of 5'-amino-2',5'-dideoxy-2'alpha-fluororibonucleosides into siRNAs improved the nuclease-resistant properties of the siRNAs without loss of their silencing efficacy. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide